Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2021-11-15 Investor Presentation
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 100% confidence The document is a detailed investor presentation dated November 15, 2021, from Jubilant Pharmova Limited. It includes extensive business overview, management team details, business segments, market dynamics, and strategic outlook. The text explicitly mentions 'Investor Presentation November 2021' and contains forward-looking statements, business structure, financial highlights, and market positioning. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The document is not a brief announcement or a certification but a comprehensive presentation aimed at investors and analysts. Therefore, the appropriate classification is Investor Presentation (IP).
2021-11-15 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a press release dated November 11, 2021, announcing a groundbreaking ceremony for a $92 million expansion of a manufacturing facility by Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharmova Limited. It is addressed to stock exchanges pursuant to a regulation requiring disclosure of material events. The content focuses on the announcement of a capital investment and expansion plans, with no financial statements, earnings data, or detailed management analysis. The document is not a report itself but a communication about a corporate event related to capital expenditure. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including significant capital investments and expansions.
2021-11-11 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of a share certificate and the intention to issue a duplicate certificate to the legal heirs. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is about notifying the stock exchanges and cautioning members about the shares involved. There is no financial data, earnings information, management discussion, or report publication. It is a regulatory announcement related to share certificates and shareholder records, not a financial report or meeting material. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-29 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains a letter addressed to stock exchanges submitting copies of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2021. It references the publication of these financial results in newspapers and requests the exchanges to take them on record. The document is about quarterly and half-year financial results, which are unaudited and cover a period shorter than a full fiscal year. The content includes substantive financial data and analysis for the interim period. Therefore, this document is a comprehensive interim/quarterly financial report rather than just an announcement or a certification. It fits the definition of an Interim / Quarterly Report (IR). H1 2022
2021-10-25 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is dated October 22, 2021, and references Regulation 33 and Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertain to financial disclosures. It contains unaudited financial results for the quarter and half year ended September 30, 2021, including standalone and consolidated results, limited review reports by auditors, detailed financial tables (income statement, balance sheet, cash flows), and notes on accounting policies and COVID-19 impact. The presence of unaudited quarterly and half-year financial results with substantive financial data and analysis indicates this is an Interim / Quarterly Report. The document is about 15,000 characters, which is substantial and contains the actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2022
2021-10-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a letter dated October 14, 2021, addressed to stock exchanges informing about a scheduled investor conference call for Jubilant Pharmova Limited. The call is to discuss the unaudited financial results for the quarter and half year ended September 30, 2021. The document includes details about the conference call logistics, dial-in numbers, and replay facility. It does not contain actual financial statements or detailed financial analysis but is an announcement of the upcoming conference call where such information will be discussed. Therefore, this document is best classified as a Call Transcript announcement or schedule, but since it is only the schedule and invitation, it fits the category of Call Transcript (CT) as it relates to the conference call event. Confidence is high as the document explicitly states it is about scheduling a conference call for financial results discussion.
2021-10-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.